Global Retinoblastoma Treatment Market 2015-2019

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Disease Overview
06.1 Understanding the Disease
06.2 Etiology
06.3 Classification
06.3.1 Bilateral Retinoblastoma
06.3.2 Unilateral Retinoblastoma
06.4 Symptoms
06.5 Diagnosis
06.5.1 Patient Examination
06.5.2 Imaging Tests
06.5.3 Biopsy Tests
06.5.4 Clinical Tests
06.6 Epidemiology
06.7 Staging
06.7.1 Intraocular Staging
06.7.2 Extraocular staging
06.8 Management
06.8.1 Cryotherapy
06.8.2 Chemotherapy
06.8.3 Photocoagulation
06.8.4 Radiation therapy
06.8.5 Surgery
06.8.6 Thermo therapy
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Pipeline Analysis
08.1 Key Information of the Pipeline Candidates
08.1.1 NTX-010
08.1.2 Racotumomab
08.1.3 Kevetrin
08.1.4 BL-8040
08.1.5 Melphalan
08.1.6 RNAi Oligonucleotide for Retinoblastoma
09. Market Segmentation by Therapeutic Class of Drugs
09.1 Alkylating Agents
09.2 Antimetabolites
09.3 Microtubule Inhibitors
09.4 Cytotoxic Antibiotics
09.5 Topoisomerase Inhibitors
09.6 Others
10. Market Segmentation by Disease Status
11. Geographical Segmentation
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2014
19.2.1 Baxter
19.2.2 Bristol-Myers Squibb
19.2.3 GlaxoSmithKline
19.2.4 Spectrum Pharmaceuticals
19.3 Other Prominent Vendors
20. Key Vendor Analysis
20.1 Baxter International Inc.
20.1.1 Key Facts
20.1.2 Business Description
20.1.3 Business Segmentation
20.1.4 Business Strategy
20.1.5 Revenue by Business Segmentation
20.1.6 Revenue by Geographical Segmentation
20.1.7 Key Developments
20.1.8 SWOT Analysis
20.2 Bristol-Myers Squibb
20.2.1 Key Facts
20.2.2 Business Overview
20.2.3 Key Product Offerings
20.2.4 Revenue by Geography
20.2.5 Business Strategy
20.2.6 Key Information
20.2.7 SWOT Analysis
20.3 GlaxoSmithKline
20.3.1 Business Overview
20.3.2 Business Segmentation
20.3.3 Business Segmentation by Revenue 2012 and 2013
20.3.4 Sales by Geography
20.3.5 Key Facts
20.3.6 Pipeline Products
20.3.7 Business Strategy
20.3.8 Key Information
20.3.9 SWOT Analysis